<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:56:56Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9325355" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9325355</identifier>
        <datestamp>2022-07-30</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="head14295" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Headache</journal-id>
              <journal-id journal-id-type="iso-abbrev">Headache</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1526-4610</journal-id>
              <journal-id journal-id-type="publisher-id">HEAD</journal-id>
              <journal-title-group>
                <journal-title>Headache</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0017-8748</issn>
              <issn pub-type="epub">1526-4610</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9325355</article-id>
              <article-id pub-id-type="pmcid">PMC9325355</article-id>
              <article-id pub-id-type="pmc-uid">9325355</article-id>
              <article-id pub-id-type="pmid">35466430</article-id>
              <article-id pub-id-type="pmid">35466430</article-id>
              <article-id pub-id-type="doi">10.1111/head.14295</article-id>
              <article-id pub-id-type="publisher-id">HEAD14295</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Submissions</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Submissions</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention</article-title>
              </title-group>
              <contrib-group>
                <contrib id="head14295-cr-0001" contrib-type="author">
                  <name>
                    <surname>Lipton</surname>
                    <given-names>Richard B.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="head14295-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0002" contrib-type="author">
                  <name>
                    <surname>Goadsby</surname>
                    <given-names>Peter J.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="head14295-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="head14295-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0003" contrib-type="author">
                  <name>
                    <surname>Dodick</surname>
                    <given-names>David W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9486-6790</contrib-id>
                  <xref rid="head14295-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0004" contrib-type="author">
                  <name>
                    <surname>McGinley</surname>
                    <given-names>James S.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="head14295-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0005" contrib-type="author">
                  <name>
                    <surname>Houts</surname>
                    <given-names>Carrie R.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="head14295-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0006" contrib-type="author">
                  <name>
                    <surname>Wirth</surname>
                    <given-names>R. J.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="head14295-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0007" contrib-type="author">
                  <name>
                    <surname>Kymes</surname>
                    <given-names>Steve</given-names>
                  </name>
                  <degrees>PhD, MHA</degrees>
                  <xref rid="head14295-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0008" contrib-type="author">
                  <name>
                    <surname>Ettrup</surname>
                    <given-names>Anders</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="head14295-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0009" contrib-type="author">
                  <name>
                    <surname>Østerberg</surname>
                    <given-names>Ole</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="head14295-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0010" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Cady</surname>
                    <given-names>Roger</given-names>
                  </name>
                  <degrees>MD, FAHS</degrees>
                  <xref rid="head14295-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                  <address>
                    <email>rcady@rkconsults.com</email>
                    <email>rkcadydoc@gmail.com</email>
                  </address>
                </contrib>
                <contrib id="head14295-cr-0011" contrib-type="author">
                  <name>
                    <surname>Ashina</surname>
                    <given-names>Messoud</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6218-4744</contrib-id>
                  <xref rid="head14295-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="head14295-cr-0012" contrib-type="author">
                  <name>
                    <surname>Buse</surname>
                    <given-names>Dawn C.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="head14295-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="head14295-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="head14295-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution-wrap>
                  <institution-id institution-id-type="ringgold">2006</institution-id>
                </institution-wrap>
                <named-content content-type="organisation-division">Department of Neurology</named-content>
                <institution>Albert Einstein College of Medicine</institution>
                <city>Bronx</city>
                <named-content content-type="country-part">New York</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="head14295-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">NIHR‐Wellcome Trust King’s Clinical Research Facility</named-content>
                <institution>King’s College Hospital</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="head14295-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Neurology</named-content>
                <institution>University of California</institution>
                <city>Los Angeles</city>
                <named-content content-type="country-part">California</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="head14295-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Mayo Clinic</institution>
                <city>Phoenix</city>
                <named-content content-type="country-part">Arizona</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="head14295-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>Vector Psychometric Group, LLC</institution>
                <city>Chapel Hill</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="head14295-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution-wrap>
                  <institution-id institution-id-type="ringgold">189622</institution-id>
                </institution-wrap>
                <institution>Lundbeck LLC</institution>
                <city>Deerfield</city>
                <named-content content-type="country-part">Illinois</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="head14295-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <institution>H. Lundbeck A/S</institution>
                <city>Copenhagen</city>
                <country country="DK">Denmark</country>
              </aff>
              <aff id="head14295-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <institution>RK Consults, LLC</institution>
                <city>Ozark</city>
                <named-content content-type="country-part">Missouri</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="head14295-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Danish Headache Center</named-content>
                <named-content content-type="organisation-division">Rigshospitalet Glostrup</named-content>
                <institution>University of Copenhagen</institution>
                <city>Copenhagen</city>
                <country country="DK">Denmark</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Roger Cady, RK Consults, LLC, Ozark, MO 65721, USA.<break/>
Email: <email>rcady@rkconsults.com</email>, <email>rkcadydoc@gmail.com</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>25</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2022</year>
              </pub-date>
              <volume>62</volume>
              <issue seq="80">6</issue>
              <issue-id pub-id-type="doi">10.1111/head.v62.6</issue-id>
              <fpage>690</fpage>
              <lpage>699</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>08</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>09</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>08</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 American Headache Society-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Headache: The Journal of Head and Face Pain</italic> published by Wiley Periodicals LLC on behalf of American Headache Society</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:HEAD-62-690.pdf"/>
              <abstract id="head14295-abs-0001">
                <title>Abstract</title>
                <sec id="head14295-sec-0001">
                  <title>Objective</title>
                  <p>To assess the utility of the novel patient‐identified (PI) most bothersome symptom (MBS) measure from PROMISE‐2, a phase 3 trial of eptinezumab for the preventive treatment of chronic migraine.</p>
                </sec>
                <sec id="head14295-sec-0002">
                  <title>Background</title>
                  <p>Relief of bothersome migraine symptoms can influence satisfaction with treatment and therapeutic persistence. Understanding the impact of preventive treatment on a PI‐MBS could improve clinical decision‐making.</p>
                </sec>
                <sec id="head14295-sec-0003">
                  <title>Methods</title>
                  <p>In PROMISE‐2, patients with chronic migraine received eptinezumab 100, 300 mg, or placebo administered intravenously every 12 weeks for up to 2 doses (<italic toggle="yes">n</italic> = 1072). PI‐MBS was an exploratory outcome requiring each patient to self‐report their MBS in response to an open‐ended question. At baseline and week 12, patients rated overall improvement in PI‐MBS. The relationships among PI‐MBS at week 12 and change in monthly migraine days (MMDs) from baseline to month 3 (weeks 9–12), Patient Global Impression of Change at week 12, and changes from baseline to week 12 in the 6‐item Headache Impact Test total, EuroQol 5‐dimensions 5‐levels visual analog scale, and 36‐item Short‐Form Health Survey component scores were assessed.</p>
                </sec>
                <sec id="head14295-sec-0004">
                  <title>Results</title>
                  <p>Treatment groups had similar baseline characteristics and reported a total of 23 unique PI‐MBS, most commonly light sensitivity (200/1072, 18.7%), nausea/vomiting (162/1072, 15.1%), and pain with activity (147/1072, 13.7%). Improvements in PI‐MBS at week 12 correlated with changes in MMDs (<italic toggle="yes">ρ</italic> = −0.49; <italic toggle="yes">p</italic> &lt; 0.0001) and other patient‐reported outcomes. Controlling for changes in MMDs, PI‐MBS improvement predicted other patient‐reported outcomes in expected directions. The magnitude of the standardized mean differences between placebo and active treatment for PI‐MBS were 0.31 (<italic toggle="yes">p</italic> &lt; 0.0001 vs. placebo) and 0.54 (<italic toggle="yes">p</italic> &lt; 0.0001 vs. placebo) for eptinezumab 100 and 300 mg, respectively.</p>
                </sec>
                <sec id="head14295-sec-0005">
                  <title>Conclusions</title>
                  <p>Improvement in PI‐MBS at week 12 was associated with improvement in other patient‐reported outcome measures, and PI‐MBS may be an important patient‐centered measure of treatment benefits in patients with chronic migraine.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="head14295-kwd-0001">chronic migraine</kwd>
                <kwd id="head14295-kwd-0002">eptinezumab</kwd>
                <kwd id="head14295-kwd-0003">most bothersome symptom</kwd>
                <kwd id="head14295-kwd-0004">patient‐identified most bothersome symptom</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>H. Lundbeck A/S
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100013327</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="6"/>
                <page-count count="10"/>
                <word-count count="6175"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>June 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:26.07.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="head14295-cit-1001"><string-name><surname>Lipton</surname><given-names>RB</given-names></string-name>, <string-name><surname>Goadsby</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Dodick</surname><given-names>DW</given-names></string-name>, et al. <article-title>Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention</article-title>. <source>Headache</source>. <year>2022</year>;<volume>62</volume>:<fpage>690</fpage>–<lpage>699</lpage>. doi:<pub-id pub-id-type="doi">10.1111/head.14295</pub-id>
<pub-id pub-id-type="pmid">35466430</pub-id></mixed-citation>
              </p>
              <fn-group id="head14295-ntgp-0001">
                <fn fn-type="funding" id="head14295-note-0001">
                  <p>
                    <bold>Funding information</bold>
                  </p>
                  <p>This study was funded by H. Lundbeck A/S, Copenhagen, Denmark</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="head14295-body-0001">
            <def-list list-content="abbreviations" id="head14295-lp-0001">
              <title>Abbreviations</title>
              <def-item>
                <term>CM</term>
                <def>
                  <p>chronic migraine</p>
                </def>
              </def-item>
              <def-item>
                <term>EQ‐5D‐5L</term>
                <def>
                  <p>EuroQol 5‐Dimensions 5‐Levels</p>
                </def>
              </def-item>
              <def-item>
                <term>HIT‐6</term>
                <def>
                  <p>6‐Item Headache Impact Test</p>
                </def>
              </def-item>
              <def-item>
                <term>MBS</term>
                <def>
                  <p>most bothersome symptom</p>
                </def>
              </def-item>
              <def-item>
                <term>MCS</term>
                <def>
                  <p>mental component summary</p>
                </def>
              </def-item>
              <def-item>
                <term>MMDs</term>
                <def>
                  <p>monthly migraine days</p>
                </def>
              </def-item>
              <def-item>
                <term>PCS</term>
                <def>
                  <p>physical component summary</p>
                </def>
              </def-item>
              <def-item>
                <term>PGIC</term>
                <def>
                  <p>Patient Global Impression of Change</p>
                </def>
              </def-item>
              <def-item>
                <term>PI‐MBS</term>
                <def>
                  <p>patient‐identified most bothersome symptom</p>
                </def>
              </def-item>
              <def-item>
                <term>PROMs</term>
                <def>
                  <p>patient‐reported outcome measures</p>
                </def>
              </def-item>
              <def-item>
                <term>SF‐36</term>
                <def>
                  <p>36‐Item Short‐Form Health Survey</p>
                </def>
              </def-item>
              <def-item>
                <term>SMDs</term>
                <def>
                  <p>standardized mean differences</p>
                </def>
              </def-item>
              <def-item>
                <term>VAS</term>
                <def>
                  <p>visual analog scale</p>
                </def>
              </def-item>
            </def-list>
            <sec id="head14295-sec-0006">
              <title>INTRODUCTION</title>
              <p>Migraine attacks are characterized by pain features (e.g., exacerbation of pain by activity), canonical associated symptoms (nausea, phonophobia, and photophobia), and other symptoms (e.g., cognitive disruption, fatigue, changes in mood, sensitivity to smell).<xref rid="head14295-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="head14295-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="head14295-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="head14295-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="head14295-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="head14295-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="head14295-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="head14295-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="head14295-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="head14295-bib-0010" ref-type="bibr"><sup>10</sup></xref> Given this vast array of symptoms, establishing priorities for assessing endpoints in clinical trials is essential. One approach was to designate the same set of symptoms as primary endpoints for everyone. This approach was used in acute treatment trials which required statistically significant separation on four co‐primary endpoints: pain, photophobia, phonophobia and nausea.<xref rid="head14295-bib-0011" ref-type="bibr"><sup>11</sup></xref> This approach was viewed as problematic for several reasons. First, not everyone has every symptom so statistical power for nausea, present in perhaps 60% of patients, is lower than the power for pain, present in 100% of patients. Second, requiring significant differences on four co‐primaries is a high bar which increases the risk of failure due to chance alone. Third, this approach does not incorporate patient priorities regarding their symptoms. Regulator guidance was modified in 2018; the number of co‐primary endpoints was reduced from four to two. Pain was retained but the associated symptoms were replaced with freedom from the patient‐designated most bothersome symptom (MBS), selected from among nausea, photophobia, and phonophobia.<xref rid="head14295-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="head14295-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="head14295-bib-0014" ref-type="bibr"><sup>14</sup></xref> Allowing the patient to select their MBS from a circumscribed list has some advantages: It reduces the number of statistical comparisons required if pain, nausea, photophobia, and phonophobia were all co‐primary endpoints in migraine trials, and it prioritizes the symptoms that generally are considered the most bothersome to the patient, providing a more patient‐centered measure. However, this approach also has a major disadvantage: For some patients, their MBS is not nausea, photophobia, or phonophobia, and limiting the available choices renders the measure less patient‐centered. An alternative approach to the limited MBS selection is an open‐ended question to identify, without restriction, the migraine‐related symptom each patient finds most bothersome, which was used in the PROMISE‐2 study.<xref rid="head14295-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="head14295-bib-0016" ref-type="bibr"><sup>16</sup></xref> We refer to this measure as the patient‐identified most bothersome symptom (PI‐MBS).</p>
              <p>In the PROMISE‐2 migraine prevention study in chronic migraine (CM), patients described their PI‐MBS at screening and were asked to rate overall improvement in the PI‐MBS using a 7‐point ordinal scale after treatment with eptinezumab or placebo. These exploratory analyses were designed to determine the potential research and clinical utility of the PI‐MBS measure for future trials and clinical practice. It was hypothesized that PI‐MBS would correlate with changes on other related patient‐reported outcome measures (PROMs), add unique clinical information above and beyond change in monthly migraine days (MMDs), and be sensitive to differences across treatment groups.</p>
            </sec>
            <sec sec-type="methods" id="head14295-sec-0007">
              <title>METHODS</title>
              <sec id="head14295-sec-0008">
                <title>Study and data source</title>
                <p>PROMISE‐2 (NCT02974153)<xref rid="head14295-bib-0015" ref-type="bibr"><sup>15</sup></xref> was a randomized, double‐blind, placebo‐controlled, parallel‐group trial that evaluated the preventive efficacy, tolerability, and safety of eptinezumab in adults with CM. Migraine diagnosis was based on the International Classification of Headache Disorders, 3rd edition (beta version).<xref rid="head14295-bib-0017" ref-type="bibr"><sup>17</sup></xref> The planned sample size for this study was 1050 randomized and treated patients: 350 patients per group provided at least 90% power to detect the primary endpoint for each comparison assuming a treatment effect of at least 1 day and a common standard deviation of 4 days or less. For the key secondary 75% migraine responder rate endpoints 90% power was achieved for the pairwise comparisons, assuming a placebo responder rate of 20% and an eptinezumab responder rate of 31%. These sample size calculations were performed as previously described.<xref rid="head14295-bib-0015" ref-type="bibr"><sup>15</sup></xref> As MBS was an exploratory endpoint, it was not included in power calculations.</p>
                <p>Eligible patients were randomized to receive eptinezumab 100, 300 mg, or placebo, administered intravenously every 12 weeks for up to 2 doses (24 weeks of treatment). Detailed methodology for PROMISE‐2 has been published.<xref rid="head14295-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="head14295-bib-0016" ref-type="bibr"><sup>16</sup></xref> This study was approved by the independent ethics committee or institutional review board at each study site; all clinical work was conducted in compliance with current Good Clinical Practices per the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines, local regulatory requirements, and the principles of the Declaration of Helsinki. All patients enrolled in the study provided written informed consent prior to participation.</p>
              </sec>
              <sec id="head14295-sec-0009">
                <title>Outcome measures</title>
                <sec id="head14295-sec-0010">
                  <title>Patient‐identified most bothersome symptom</title>
                  <p>Patients were asked to verbally describe the MBS that they associated with CM at the screening visit. This question was open‐ended and there were no limits regarding the type of migraine‐associated symptom, the specific migraine attack, or the phase of migraine attack (e.g., premonitory/prodrome). Prior to analysis, the study investigator categorized the PI‐MBS into 1 of 9 predefined categories: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, or other/specify. The other/specify option was used for PI‐MBS responses not readily classified into a predefined category, reports of multiple symptoms, and cases in which the investigator chose to include specific details of the patient's description. The verbatim descriptions included in the other/specify category were reviewed and then classified into a predefined symptom group (when possible) or were assigned to a new symptom category.</p>
                  <p>The open‐ended symptom categories constructed by investigators were reduced into 3 broad symptom classes by clinical (R.B.L.) and methodological experts (J.S.M., R.J.W.). These 3 classes were as follows.
<list list-type="order" id="head14295-list-0001"><list-item><p>Pain related to migraine symptoms (pain‐related): eye pain, headache, non‐anatomical/extracephalic pain, pain‐anatomical, pain with activity, and throbbing/pulsation.</p></list-item><list-item><p>Canonical/traditional symptoms (canonical): nausea/vomiting, sensitivity to light, and sensitivity to sound.</p></list-item><list-item><p>Other symptoms (other): allodynia, aura manifestations, cognitive disruption, dizziness, fatigue, inactivity, mood changes, neck pain, pressure/tightness, sensitivity to smell, sensory disturbance, sleep disturbance, speech difficulty, vision impacts, multiple, and other. Neck pain was included in the “other” category because it is unique from a clinical standpoint relative to the other pain responses.</p></list-item></list>
</p>
                  <p>PI‐MBS was identified at screening and reaffirmed at Day 0. [new sentence]: At weeks 4, 8, 12, 16, 20, 24, and 32, patients were asked to rate the overall improvement in the PI‐MBS they identified at the start of the study on an ordinal scale (1 = very much worse, 2 = much worse, 3 = minimally worse, 4 = no change, 5 = minimally improved, 6 = much improved, and 7 = very much improved). The current work focused on improvement in PI‐MBS at week 12.</p>
                </sec>
                <sec id="head14295-sec-0011">
                  <title>Monthly migraine days</title>
                  <p>The number of days with migraine that occurred during the 28‐day screening period was used for the patients’ baseline MMDs. The frequency of MMDs during the study period was calculated over 4‐week intervals.<xref rid="head14295-bib-0015" ref-type="bibr"><sup>15</sup></xref> If the headache diary was completed for ≥21 days in a 4‐week period, the observed frequency was normalized to 28 days. If the diary was completed for &lt;21 days in a 4‐week period, the findings were a weighted function of the observed data for the current interval and the results for previous interval with the weight being proportional to the number of completed days. The current work focused on change in MMDs from baseline to weeks 9–12, the final 4 weeks of the dosing interval.</p>
                </sec>
                <sec id="head14295-sec-0012">
                  <title>Other patient‐reported outcome measures</title>
                  <p>In addition to PI‐MBS, PROMISE‐2 captured patient responses to a Patient Global Impression of Change (PGIC) item, the 36‐item Short‐Form Health Survey (SF‐36), EuroQol 5‐Dimensions 5‐Levels (EQ‐5D‐5L), and 6‐item Headache Impact Test (HIT‐6).</p>
                  <p>The PGIC consists of a single question<xref rid="head14295-bib-0018" ref-type="bibr"><sup>18</sup></xref> regarding how patients feel that their overall condition has changed from the start of the study. Patients were asked to respond to the question, “Since first receiving study drug in this study, how would you describe the change (if any) in activity limitations, symptoms, emotions, and overall quality of life, as related to your migraine?” using a 7‐point ordinal scale identical to the one used for PI‐MBS (1 = very much worse, 2 = much worse, 3 = minimally worse, 4 = no change, 5 = minimally improved, 6 = much improved, and 7 = very much improved). PGIC scores were evaluated every 4 weeks; this analysis focused on PGIC at week 12.</p>
                  <p>The SF‐36 comprises 36 questions that cover 8 domains of health; 2 component scores can also be calculated, a physical component summary (PCS) and a mental component summary (MCS) score.<xref rid="head14295-bib-0019" ref-type="bibr"><sup>19</sup></xref> During the PROMISE‐2 study, PCS and MCS scores were computed at weeks 4, 12, 16, 24, and 32. The change in SF‐36 scores from baseline to week 12 was evaluated for this analysis.</p>
                  <p>In addition to five individual dimensions of health‐related quality of life, the EQ‐5D‐5L<xref rid="head14295-bib-0020" ref-type="bibr"><sup>20</sup></xref> includes a visual analog scale (VAS) on which patients rate their overall health from 0 (the worst health imaginable) to 100 (the best health imaginable). VAS scores were collected at weeks 4, 12, 16, 24, and 32. The change in the EQ‐5D‐5L VAS from baseline to week 12 was evaluated in the current analysis.</p>
                  <p>The HIT‐6<xref rid="head14295-bib-0021" ref-type="bibr"><sup>21</sup></xref> is a 6‐item PROM used to assess the impact of headache on daily life; it comprises six questions and a total summed score is calculated. During PROMISE‐2, total scores were calculated at weeks 4, 12, 16, 24, and 32. For this analysis, change in HIT‐6 total scores from baseline to week 12 was evaluated.</p>
                </sec>
              </sec>
              <sec id="head14295-sec-0013">
                <title>Statistical analyses</title>
                <p>All of the following post hoc analyses were conducted using SAS v9.4 (SAS Institute, Inc., Cary, NC, USA). The standard significance threshold of 0.05, with no correction for multiple comparisons, was used to determine statistical significance (i.e., differences between groups). With the exception of MMDs, missing PROM data were not imputed, and all available non‐missing data were used for analyses. PROM analyses largely focused on pooled treatment groups, an approach that has been previously utilized.<xref rid="head14295-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="head14295-bib-0023" ref-type="bibr"><sup>23</sup></xref>
</p>
                <sec id="head14295-sec-0014">
                  <title>Assessing the ability to pool individual PI‐MBS into a single measure</title>
                  <p>One‐way analysis of variance (ANOVA) models and chi‐squared tests were used to evaluate demographic variables across PI‐MBS classes. One‐way ANOVA (treating PI‐MBS improvement scores as continuous) and ordinal proportional odds regression (treating PI‐MBS improvement scores as ordinal) models were used to compare PI‐MBS improvement across PI‐MBS classes, with 2‐sided <italic toggle="yes">p</italic> values presented. To assess if the different classes of PI‐MBS functioned uniquely, invariance of the relations among PI‐MBS and PROM scores were evaluated using Pearson (when comparing with a continuous variable) and Spearman (when comparing with a categorical/ordinal variable) correlations. The similarity of relationships among PI‐MBS improvement and change in other PROMs was evaluated using Bartlett's likelihood ratio test of the homogeneity of the within‐group covariance matrices.<xref rid="head14295-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="head14295-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="head14295-bib-0026" ref-type="bibr"><sup>26</sup></xref> A statistically non‐significant value (i.e., <italic toggle="yes">p</italic> &gt; 0.05) for the test for heterogeneity was pre‐specified as the criterion for pooling over the PI‐MBS classes.</p>
                </sec>
                <sec id="head14295-sec-0015">
                  <title>Evaluating the unique effects of PI‐MBS</title>
                  <p>Linear regression models were fit to test the unique effect of PI‐MBS improvement, while controlling for change in MMDs. For each model, standardized regression coefficients were calculated to provide measures of effect size. Standardized regression coefficients were computed by dividing a parameter estimate by the ratio of the sample standard deviation of the dependent variable to the sample standard deviation of the regressor. Dependent variables were HIT‐6 change, PGIC, EQ‐5D‐5L change, SF‐36 MCS change, and SF‐36 PCS change.</p>
                </sec>
                <sec id="head14295-sec-0016">
                  <title>Known‐groups analyses</title>
                  <p>Three sets of distinct groups were created for the post hoc known‐groups analyses. First, using MMDs as an anchor, the “improved” group comprised those patients who decreased their MMDs by 50% or more at week 12 relative to baseline (≥50% MMD response), a common benchmark used for clinical migraine research.<xref rid="head14295-bib-0027" ref-type="bibr"><sup>27</sup></xref> The “not improved” group were individuals who did not decrease their MMDs to the 50% threshold. Second, using the HIT‐6 scores as an anchor, the “improved” group comprised those patients who decreased their HIT‐6 total score by 6 or more points at week 12 relative to baseline; the “not improved” group were individuals who did not meet this established clinically meaningful change threshold.<xref rid="head14295-bib-0023" ref-type="bibr"><sup>23</sup></xref> Third, the eptinezumab 100 and 300 mg treatment groups were compared with placebo. Prior research has demonstrated the efficacy of eptinezumab as a preventive migraine treatment,<xref rid="head14295-bib-0015" ref-type="bibr"><sup>15</sup></xref> and the active treatment groups were expected to be clearly differentiated from placebo.</p>
                  <p>All group differences were examined against typical effect size (standardized mean differences [SMDs]) criteria, where 0.2 indicated a small effect, 0.5 a moderate effect, and 0.8 or greater a large effect size.<xref rid="head14295-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="head14295-bib-0029" ref-type="bibr"><sup>29</sup></xref> The SMDs were calculated by dividing the model‐implied group differences by the root mean square error from linear regression models treating PI‐MBS improvement as continuous (scores ranged from 1 = very much worse to 7 = very much improved). Additionally, odds ratios were calculated from proportional odds models that treated PI‐MBS improvement as ordinal.</p>
                </sec>
                <sec id="head14295-sec-0017">
                  <title>Comparing treatment effect sizes</title>
                  <p>Linear regression models were fit to estimate the magnitude of treatment effects. The dependent variables were PI‐MBS improvement, MMD change, HIT‐6 change, PGIC, EQ‐5D‐5L change, SF‐36 MCS change, and SF‐36‐PCS change. For each model, SMDs were calculated to compare the magnitude of treatment effects across PI‐MBS classes. The SMDs were calculated by dividing the model‐implied treatment group differences (e.g., 300 mg vs. placebo and 100 mg vs. placebo) by the root mean square error, which provides an effect size measure similar to Cohen's <italic toggle="yes">d</italic>.<xref rid="head14295-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="head14295-bib-0029" ref-type="bibr"><sup>29</sup></xref>
</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="head14295-sec-0018">
              <title>RESULTS</title>
              <sec id="head14295-sec-0019">
                <title>Patients and PI‐MBS at baseline</title>
                <p>A total of 1072 adults with CM participated in PROMISE‐2. The mean age was 40.5 years; 88.2% of patients were female, and 91.0% were white.<xref rid="head14295-bib-0015" ref-type="bibr"><sup>15</sup></xref> At baseline, the mean age at migraine diagnosis was 22.5 years, the mean duration of CM was 11.8 years, and the mean MMDs during screening was 16.1.</p>
                <p>Patients reported a total of 23 unique PI‐MBS, most commonly light sensitivity (18.7%), nausea, vomiting (15.1%), pain with activity (13.7%), pain (12.4%), headache (11.2%), sound sensitivity (7.3%), throbbing/pulsating pain (4.7%), cognitive disruption (4.1%), fatigue (2.4%), mood changes (1.5%), and sensitivity to smell (0.9%; Table <xref rid="head14295-tbl-0001" ref-type="table">1</xref>). More than 80% of patients identified a symptom that fell within either the pain‐related or canonical PI‐MBS classes (pain‐related, 462/1072 [43.1%]; canonical, 440/1072 [41.0%]). The remaining 15.9% (170/1072) fell within the “other” PI‐MBS class.</p>
                <table-wrap position="float" id="head14295-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>PI‐MBS associated with chronic migraine at screening</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Patients, <italic toggle="yes">n</italic> (%)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Total (<italic toggle="yes">N</italic> = 1072)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Pain symptoms</td>
                        <td align="char" char="(" rowspan="1" colspan="1">462 (43.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pain exacerbation with activity<xref rid="head14295-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">147 (13.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pain<xref rid="head14295-note-0003" ref-type="table-fn"><sup>
a
</sup></xref>, <xref rid="head14295-note-0004" ref-type="table-fn"><sup>
b
</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">133 (12.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Headache<xref rid="head14295-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">120 (11.2)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Throbbing/pulsation<xref rid="head14295-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">50 (4.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Eye pain<xref rid="head14295-note-0004" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6 (0.6)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anatomical pain<xref rid="head14295-note-0004" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6 (0.6)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Canonical/traditional symptoms</td>
                        <td align="char" char="(" rowspan="1" colspan="1">440 (41.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sensitivity to light<xref rid="head14295-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">200 (18.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nausea/vomiting<xref rid="head14295-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">162 (15.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sensitivity to sound<xref rid="head14295-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">78 (7.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Other symptoms</td>
                        <td align="char" char="(" rowspan="1" colspan="1">170 (15.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cognitive disruption</td>
                        <td align="char" char="(" rowspan="1" colspan="1">44 (4.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fatigue</td>
                        <td align="char" char="(" rowspan="1" colspan="1">26 (2.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mood changes</td>
                        <td align="char" char="(" rowspan="1" colspan="1">16 (1.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sensitivity to smell</td>
                        <td align="char" char="(" rowspan="1" colspan="1">10 (0.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Visual impact<xref rid="head14295-note-0005" ref-type="table-fn"><sup>c</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">8 (0.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aura symptoms (including visual and physical experiences)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">7 (0.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pressure/tightness</td>
                        <td align="char" char="(" rowspan="1" colspan="1">7 (0.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dizziness</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5 (0.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Neck pain</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5 (0.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Allodynia</td>
                        <td align="char" char="(" rowspan="1" colspan="1">3 (0.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Inactivity</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2 (0.2)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sensory disturbance<xref rid="head14295-note-0005" ref-type="table-fn"><sup>c</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">1 (0.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sleep disturbance</td>
                        <td align="char" char="(" rowspan="1" colspan="1">1 (0.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Speech difficulty<xref rid="head14295-note-0005" ref-type="table-fn"><sup>c</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">1 (0.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multiple<xref rid="head14295-note-0006" ref-type="table-fn"><sup>d</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">27 (2.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td>
                        <td align="char" char="(" rowspan="1" colspan="1">7 (0.7)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="head14295-ntgp-0002">
                    <fn id="head14295-note-0002">
                      <p>Abbreviations: ICHD‐3, International Classification of Headache Disorders, 3rd edition; PI‐MBS, patient‐identified most bothersome symptom.</p>
                    </fn>
                    <fn id="head14295-note-0003">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Included in the International Classification of Headache Disorders, 3rd edition (ICHD‐3) diagnostic criteria.</p>
                    </fn>
                    <fn id="head14295-note-0004">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Extracephalic pain (patients were not limited in their description of PI‐MBS).</p>
                    </fn>
                    <fn id="head14295-note-0005">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Could be related to ICHD‐3 canonical symptoms such as aura and photophobia or other visual impacts not considered migraine‐defining, such as blurry vision.</p>
                    </fn>
                    <fn id="head14295-note-0006">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Patient reported &gt;1 type of PI‐MBS.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="head14295-sec-0020">
                <title>Pooling individual symptoms into a single PI‐MBS measure</title>
                <p>In this analysis, individual PI‐MBS were first categorized into 3 classes (pain‐related, canonical, and other) to determine if different classes of PI‐MBS could be combined for subsequent analyses.</p>
                <p>Demographics and baseline clinical characteristics stratified by PI‐MBS class are shown in Table <xref rid="head14295-tbl-0002" ref-type="table">2</xref>. PI‐MBS classes did not differ with regard to sex (<italic toggle="yes">p</italic> = 0.328), age of migraine diagnosis (<italic toggle="yes">p</italic> = 0.512), or migraine days during screening (<italic toggle="yes">p</italic> = 0.530); between‐group differences in age (<italic toggle="yes">p</italic> = 0.016), duration of migraine diagnosis (<italic toggle="yes">p</italic> = 0.011), and race <italic toggle="yes">(p</italic> = 0.005) could not be excluded, and their clinical meaningfulness remains unknown. Across PI‐MBS classes, mean age differed by no more than 2 years (41.7, 39.7, and 39.8 years in the pain‐related, canonical, and other classes, respectively) and mean duration of diagnosis by no more than 2.5 years (19.2 years, 16.9 years, and 18.0 years, respectively). In all PI‐MBS classes, the majority of patients were white (94.8%, 88.2%, and 87.7% in the pain‐related, canonical, and other classes, respectively).</p>
                <table-wrap position="float" id="head14295-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Demographics and baseline clinical characteristics stratified by PI‐MBS class</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">Pain‐related <italic toggle="yes">N</italic> = 462</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Canonical <italic toggle="yes">N</italic> = 440</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Other <italic toggle="yes">N</italic> = 170</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age (years), mean (SD)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">41.7 (11.0)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">39.7 (11.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">39.8 (11.5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td>
                        <td align="char" char="(" rowspan="1" colspan="1">62 (13.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">47 (10.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">17 (10.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td>
                        <td align="char" char="(" rowspan="1" colspan="1">400 (86.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">393 (89.3)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">153 (90.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Race, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td>
                        <td align="char" char="(" rowspan="1" colspan="1">438 (94.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">388 (88.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">149 (87.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black or African American</td>
                        <td align="char" char="(" rowspan="1" colspan="1">21 (4.6.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">44 (10.0)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">17 (10.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other<xref rid="head14295-note-0008" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="char" char="(" rowspan="1" colspan="1">3 (0.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">8 (1.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4 (2.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age at migraine diagnosis (years), mean (SD)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">22.4 (10.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">22.8 (9.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">21.8 (9.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Duration of migraine diagnosis (years), mean (SD)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">19.2 (11.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">16.9 (11.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">18.0 (12.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Screening period migraine days, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;17 days</td>
                        <td align="char" char="(" rowspan="1" colspan="1">252 (54.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">237 (53.9)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">100 (58.8)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥17 days</td>
                        <td align="char" char="(" rowspan="1" colspan="1">210 (45.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">203 (46.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">70 (41.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Treatment group, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Eptinezumab 100 mg</td>
                        <td align="char" char="(" rowspan="1" colspan="1">158 (34.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">144 (32.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">54 (31.8)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Eptinezumab 300 mg</td>
                        <td align="char" char="(" rowspan="1" colspan="1">154 (33.3)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">138 (31.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">58 (34.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Placebo</td>
                        <td align="char" char="(" rowspan="1" colspan="1">150 (32.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">158 (35.9)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">58 (34.1)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="head14295-ntgp-0003">
                    <fn id="head14295-note-0007">
                      <p>Abbreviations: PI‐MBS, patient‐identified most bothersome symptom; SD, standard deviation.</p>
                    </fn>
                    <fn id="head14295-note-0008">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Other includes Asian, Native American or Alaska Native, Native Hawaiian or Other Pacific Islander, multiple races, and other. Within the PROMISE‐2 safety population, Asians, American Indian/Alaskan Native, Native Hawaiian/other Pacific Islander, and Multiple Races represented 3/1072 (&lt;1%), 3/1072 (&lt;1%), 1/1072 (&lt;1%), and 7/1072 (&lt;1%) of the overall population, respectively.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Bartlett's likelihood ratio test of the homogeneity of the within‐group covariance matrices showed that the relationships among the PROMs did not differ across the 3 PI‐MBS classes (<italic toggle="yes">p</italic> = 0.052). Furthermore, at week 12, a difference in reported improvement for PI‐MBS classes was not found based on an ordinal proportional odds model (χ<sup>2</sup>[2] = 3.12, <italic toggle="yes">p</italic> = 0.210) or analysis of variance (<italic toggle="yes">F</italic>[2, 1022] = 1.91, <italic toggle="yes">p</italic> = 0.148) models (Table <xref rid="head14295-tbl-0003" ref-type="table">3</xref>). These results supported the use of a single PI‐MBS variable (with patients identifying their MBS among the 3 classes) in subsequent analyses.</p>
                <table-wrap position="float" id="head14295-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>PI‐MBS improvement at week 12 stratified by PI‐MBS class</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Patients, <italic toggle="yes">n</italic> (%)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Pain‐related</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Canonical</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Other</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Very much worse</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Much worse</td>
                        <td align="left" rowspan="1" colspan="1">5 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Minimally worse</td>
                        <td align="left" rowspan="1" colspan="1">12 (2.7)</td>
                        <td align="left" rowspan="1" colspan="1">7 (1.7)</td>
                        <td align="left" rowspan="1" colspan="1">7 (4.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">No change</td>
                        <td align="left" rowspan="1" colspan="1">99 (22.3)</td>
                        <td align="left" rowspan="1" colspan="1">83 (19.7)</td>
                        <td align="left" rowspan="1" colspan="1">32 (20.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Minimally improved</td>
                        <td align="left" rowspan="1" colspan="1">118 (26.6)</td>
                        <td align="left" rowspan="1" colspan="1">106 (25.2)</td>
                        <td align="left" rowspan="1" colspan="1">46 (28.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Much improved</td>
                        <td align="left" rowspan="1" colspan="1">135 (30.4)</td>
                        <td align="left" rowspan="1" colspan="1">152 (36.1)</td>
                        <td align="left" rowspan="1" colspan="1">47 (29.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Very much improved</td>
                        <td align="left" rowspan="1" colspan="1">75 (16.9)</td>
                        <td align="left" rowspan="1" colspan="1">72 (17.1)</td>
                        <td align="left" rowspan="1" colspan="1">27 (16.9)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="head14295-ntgp-0004">
                    <title>Note</title>
                    <fn id="head14295-note-0009">
                      <p>Due to missing data on PI‐MBS at week 12, the total sample size for these analyses was <italic toggle="yes">n</italic> = 1025 (Pain‐Related: <italic toggle="yes">n</italic> = 444; Canonical: <italic toggle="yes">n</italic> = 421; Other: <italic toggle="yes">n</italic> = 160).</p>
                    </fn>
                    <fn id="head14295-note-0010">
                      <p>Abbreviation: PI‐MBS, patient‐identified most bothersome symptom.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="head14295-sec-0021">
                <title>Relationship and unique effects of PI‐MBS on other PROMs and MMDs</title>
                <p>Correlational analyses (to support convergent validity claims) were used to determine the relationship between PI‐MBS classes and changes in theoretically related PROMs at week 12 (Table <xref rid="head14295-tbl-0004" ref-type="table">4</xref>). PI‐MBS improvement at week 12 showed a correlation with changes or improvement on all other PROMs evaluated (<italic toggle="yes">p</italic> &lt; 0.0001). Strong correlations were observed between PI‐MBS improvement and changes in headache/migraine‐specific outcomes, such as the HIT‐6 total scores and MMDs (<italic toggle="yes">r</italic> ~ 0.5). Moderate/weaker correlations were found between PI‐MBS improvement and changes in non‒headache/migraine‐specific PROMs such as the SF‐36 PCS, SF‐36 MCS, and EQ‐5D‐5L VAS (<italic toggle="yes">r</italic> = 0.21–0.35). Of note, the correlation between PI‐MBS improvement and PGIC was very strong (<italic toggle="yes">r</italic> ~ 0.85), which was expected given the similarity between both the item content and response options.</p>
                <table-wrap position="float" id="head14295-tbl-0004" content-type="TABLE">
                  <label>TABLE 4</label>
                  <caption>
                    <p>Relationships between PI‐MBS and changes in related PROMs at Week 12</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">PI‐MBS</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">∆MMDs</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">∆HIT‐6</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">PGIC</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">∆EQ‐5D‐5L</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">∆SF‐36 MCS</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">∆SF‐36 PCS</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PI‐MBS</td>
                        <td align="char" char="." style="background-color:#DDDDDD" rowspan="1" colspan="1">1.00</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.49</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.53</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.85</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.25</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.35</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.22</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">∆MMDs</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.49</td>
                        <td align="char" char="." style="background-color:#DDDDDD" rowspan="1" colspan="1">1.00</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.49</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.49</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.22</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.29</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.26</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">∆HIT‐6</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.50</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.48</td>
                        <td align="char" char="." style="background-color:#DDDDDD" rowspan="1" colspan="1">1.00</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.57</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.36</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.43</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.39</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PGIC</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.84</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.49</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.54</td>
                        <td align="char" char="." style="background-color:#DDDDDD" rowspan="1" colspan="1">1.00</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.28</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.34</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.28</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">∆EQ‐5D‐5L</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.25</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.21</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.37</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.28</td>
                        <td align="char" char="." style="background-color:#DDDDDD" rowspan="1" colspan="1">1.00</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.38</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.31</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">∆SF‐36 MCS</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.34</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.29</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.45</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.34</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.39</td>
                        <td align="char" char="." style="background-color:#DDDDDD" rowspan="1" colspan="1">1.00</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">∆SF‐36 PCS</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.21</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.28</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.42</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.27</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.35</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.13</td>
                        <td align="char" char="." style="background-color:#DDDDDD" rowspan="1" colspan="1">1.00</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="head14295-ntgp-0005">
                    <title>Note</title>
                    <fn id="head14295-note-0011">
                      <p>Pearson correlation coefficients are on the bottom diagonal (below 1 s) and Spearman correlation coefficients are on the top diagonal (above 1 s).</p>
                    </fn>
                    <fn id="head14295-note-0012">
                      <p>Abbreviations: ∆, change from baseline to week 12; EQ‐5D‐5L, EuroQol 5‐dimension 5‐level (visual analog scale); HIT‐6, 6‐Item Headache Impact Test; MCS, mental component summary score; MMDs, monthly migraine days; PCS, physical component summary score; PGIC, Patient Global Impression of Change; PI‐MBS, patient‐identified most bothersome symptom; PROMs, patient‐reported outcomes measures; SF‐36, 36‐item Short‐Form Health Survey.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Regression analysis was used to determine the unique effects of PI‐MBS in predicting reference measure scores, after controlling for MMD changes. Across all 5 PROMs, PI‐MBS improvement predicted better outcomes above and beyond change in the MMDs (<italic toggle="yes">p</italic> &lt; 0.003 for all). For 4 of the 5 PROMs (all but SF‐36 MCS), PI‐MBS had larger standardized effects compared with change in MMDs (Table <xref rid="head14295-tbl-0005" ref-type="table">5</xref>).</p>
                <table-wrap position="float" id="head14295-tbl-0005" content-type="TABLE">
                  <label>TABLE 5</label>
                  <caption>
                    <p>Standardized regression coefficients for MMD and PI‐MBS effects on related PROMs</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1"/>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">∆HIT‐6</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">PGIC<xref rid="head14295-note-0014" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">∆EQ‐5D‐5L</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">∆SF‐36 MCS</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">∆SF‐36 PCS</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Std est</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Std est</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Std est</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Std est</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Std est</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">∆MMDs</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.31</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.21</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.12</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.001</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.16</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.23</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PI‐MBS</td>
                        <td align="char" char="." rowspan="1" colspan="1">−0.35</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="char" char="." rowspan="1" colspan="1">1.82</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.19</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.27</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.10</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.003</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="head14295-ntgp-0006">
                    <fn id="head14295-note-0013">
                      <p>Abbreviations: ∆, change from baseline to week 12; EQ‐5D‐5L, EuroQol 5‐dimension 5‐level (visual analog scale); HIT‐6, 6‐Item Headache Impact Test; MCS, mental component summary score; MMDs, monthly migraine days; PCS, physical component summary score; PGIC, Patient Global Impression of Change; PI‐MBS, patient‐identified most bothersome symptom; PROMs, patient‐reported outcomes measures; SF‐36, 36‐item Short‐Form Health Survey; Std est, standardized estimate.</p>
                    </fn>
                    <fn id="head14295-note-0014">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Based on ordinal proportional odds model.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="head14295-sec-0022">
                <title>Known‐groups analyses</title>
                <p>In known‐groups analyses, PI‐MBS improvement ratings conformed to expectations, both in terms of reported descriptive values (mean, standard deviation, <italic toggle="yes">n</italic>, %) and with respect to the outcome of tests of differences between the groups (Table <xref rid="head14295-tbl-0006" ref-type="table">6</xref>). Both the ≥50% MMD responders and HIT‐6 total score responders reported greater improvement in PI‐MBS compared with the respective non‐responding groups (Figure <xref rid="head14295-fig-0001" ref-type="fig">1A,B</xref>). The effect size of each difference was large, indicating that the PI‐MBS improvement rating can distinguish between clinically meaningful groups. Moreover, results aligned with the expected treatment results, with the eptinezumab 300 mg and 100 mg doses clearly differentiated from placebo according to PI‐MBS improvement (Table <xref rid="head14295-tbl-0006" ref-type="table">6</xref>; Figure <xref rid="head14295-fig-0001" ref-type="fig">1C</xref>).</p>
                <table-wrap position="float" id="head14295-tbl-0006" content-type="TABLE">
                  <label>TABLE 6</label>
                  <caption>
                    <p>PI‐MBS improvement known‐groups analyses: ≥50% MMD response, meaningful change in HIT‐6 total score, and treatment groups</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="bottom" colspan="1">Group</th>
                        <th align="left" rowspan="2" valign="bottom" colspan="1">
                          <italic toggle="yes">N</italic>
                        </th>
                        <th align="left" rowspan="2" valign="bottom" colspan="1">Mean (SD)</th>
                        <th align="left" colspan="7" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1"><italic toggle="yes">n</italic> (%)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">1 Very much worse</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">2 Much worse</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">3 Minimally worse</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">4 No change</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">5 Minimally improved</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">6 Much improved</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">7 Very much improved</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥50% MMD responders<xref rid="head14295-note-0017" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td>
                        <td align="left" rowspan="1" colspan="1">550</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.9 (1.0)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2 (0.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">8 (1.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">38 (6.9)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">117 (21.3)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">237 (43.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">148 (26.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td>
                        <td align="left" rowspan="1" colspan="1">475</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4.8 (1.0)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4 (0.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">18 (3.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">176 (37.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">153 (32.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">97 (20.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">26 (5.5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HIT‐6 meaningful change<xref rid="head14295-note-0018" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td>
                        <td align="left" rowspan="1" colspan="1">485</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.9 (0.9)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2 (0.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">3 (0.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">32 (6.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">96 (19.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">210 (43.3)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">142 (29.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td>
                        <td align="left" rowspan="1" colspan="1">539</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4.9 (1.0)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4 (0.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">23 (4.3)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">182 (33.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">173 (32.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">124 (23.0)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">32 (5.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Treatment</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Eptinezumab 100 mg<xref rid="head14295-note-0019" ref-type="table-fn"><sup>c</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1">344</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.4 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">12 (3.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">61 (17.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">84 (24.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">130 (37.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">54 (15.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Eptinezumab 300 mg<xref rid="head14295-note-0020" ref-type="table-fn"><sup>d</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1">338</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.7 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">52 (15.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">75 (22.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">128 (37.9)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">79 (23.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Placebo</td>
                        <td align="left" rowspan="1" colspan="1">343</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.1 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">12 (3.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">101 (29.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">111 (32.3)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">76 (22.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">41 (12.0)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="head14295-ntgp-0007">
                    <title>Note</title>
                    <fn id="head14295-note-0015">
                      <p>Effect sizes were quantified as standardized mean difference.</p>
                    </fn>
                    <fn id="head14295-note-0016">
                      <p>Abbreviations: HIT‐6, 6‐item Headache Impact Test; MBS, most bother symptom; MMD, monthly migraine days; SD, standard deviation.</p>
                    </fn>
                    <fn id="head14295-note-0017">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Effect size 1.04 (<italic toggle="yes">p</italic> &lt; 0.0001); odds ratio 6.74 (<italic toggle="yes">p</italic> &lt; 0.0001).</p>
                    </fn>
                    <fn id="head14295-note-0018">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Effect size 1.05 (<italic toggle="yes">p</italic> &lt; 0.0001); odds ratio 6.73 (<italic toggle="yes">p</italic> &lt; 0.0001).</p>
                    </fn>
                    <fn id="head14295-note-0019">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Eptinezumab 100 mg versus placebo: effect size 0.31 <italic toggle="yes">(p</italic> &lt; 0.0001); odds ratio 1.85 (<italic toggle="yes">p</italic> &lt; 0.0001).</p>
                    </fn>
                    <fn id="head14295-note-0020">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Eptinezumab 300 mg versus placebo: effect size 0.54 (<italic toggle="yes">p</italic> &lt; 0.0001); odds ratio 2.72 (<italic toggle="yes">p</italic> &lt; 0.0001).</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <fig position="float" fig-type="FIGURE" id="head14295-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Known‐groups analysis of patient‐identified most bothersome symptom (PI‐MBS) improvement by (A) ≥50% monthly migraine days (MMD) response, (B) clinically meaningful change in the 6‐item Headache Impact Test (HIT‐6) total score, and (C) treatment group. PI‐MBS improvement ranged from 1 = very much worse, 2 = much worse, 3 = minimally worse, 4 = no change, 5 = minimally improved, 6 = much improved, to 7 = very much improved</p>
                  </caption>
                  <graphic xlink:href="HEAD-62-690-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
              </sec>
              <sec id="head14295-sec-0023">
                <title>Treatment effect sizes</title>
                <p>The magnitude of treatment effects was generally greater for PI‐MBS improvement at week 12 compared to changes in MMD from baseline to weeks 9–12. For patients receiving eptinezumab 300 mg, the overall effect size versus placebo was 0.54 (<italic toggle="yes">p</italic> &lt; 0.0001), and for those receiving 100 mg, the effect size versus placebo was slightly smaller (0.31; <italic toggle="yes">p</italic> &lt; 0.0001; Table <xref rid="head14295-tbl-0006" ref-type="table">6</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="head14295-sec-0024">
              <title>DISCUSSION</title>
              <p>In the pivotal phase 3 PROMISE‐2 study of intravenous eptinezumab, the novel open‐ended PI‐MBS measure was used, and the effect of preventive treatment on the patients’ PI‐MBS was measured during the trial.<xref rid="head14295-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="head14295-bib-0016" ref-type="bibr"><sup>16</sup></xref> The resultant data were utilized in the current multifaceted post hoc analyses to empirically evaluate the appropriateness and clinical utility of the PI‐MBS for preventive migraine research.</p>
              <p>The finding that PI‐MBS improvement at week 12 consistently predicted improvement on PROMs, controlling for changes in MMDs, suggests that the PI‐MBS may add clinically useful information reflecting patients’ symptom experience. Though we did not power the study for this exploratory endpoint, the statistically significant results suggest that power was adequate.</p>
              <p>Known‐groups analyses demonstrated that the PI‐MBS improvement ratings were able to distinguish between clinically meaningful patient subgroups. Patients who were ≥50% MMD responders and patients who were HIT‐6 total score responders reported greater improvement in PI‐MBS compared with the respective non‐responding groups, as did patients treated with eptinezumab compared with placebo. The magnitude of treatment effects for all PI‐MBS appears to be in line with the eptinezumab dose (100 mg or 300 mg), with the 300 mg dose having a greater effect size than the 100 mg dose (0.54 and 0.31, respectively; both <italic toggle="yes">p</italic> &lt; 0.0001 vs. placebo).</p>
              <p>Advances in our understanding of the pathophysiologic mechanisms underlying migraine have resulted in the development of several new drugs and treatment classes for both preventive and acute migraine treatment.<xref rid="head14295-bib-0030" ref-type="bibr"><sup>30</sup></xref> However, across the multitude of clinical trials of migraine preventive treatments undertaken to date, the outcomes and measures vary, particularly the inclusion of PROMs.<xref rid="head14295-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="head14295-bib-0027" ref-type="bibr"><sup>27</sup></xref> Patient‐centric measures that can identify and integrate the most bothersome aspects of the migraine experience with clinical efficacy data could inform and improve clinical decision‐making and enhance the ability to prescribe appropriate treatment.<xref rid="head14295-bib-0027" ref-type="bibr"><sup>27</sup></xref> Identification and understanding of how preventive treatment can impact PI‐MBS has the potential to make future clinical trials more patient‐centered and to provide support for the benefits of treatment.</p>
              <p>A primary limitation of this study is the post hoc nature of the analysis, and additional studies will be necessary to confirm these findings. It is possible that interviewer bias confounded the identification of the PI‐MBS as there was no standardized script at the baseline screening visit to elicit patient MBSs. Additionally, while the PI‐MBS and PGIC correlate very highly, and the PI‐MBS appears more specific in defining a migraine‐related factor driving outcomes, the PGIC is conceptually and practically simpler. In this study, only changes in the PI‐MBS identified at screening were evaluated, and it is not known if the PI‐MBS for any given individual changed (to a different PI‐MBS) over the course of the trial. Additionally, patients in this study were not asked when their PI‐MBS occurred (ictal/interictal phase); thus, no analysis was done to investigate if this affected scores. This study also included headache pain as a PI‐MBS, where traditionally studies of MBS have been of the cardinal symptoms other than headache pain (i.e., nausea, photophobia, and phonophobia). In future studies, it may be useful to explore a series of bothersome symptoms rather than a single PI‐MBS, and to record which phase of migraine the symptoms occur for that patient.</p>
            </sec>
            <sec sec-type="conclusions" id="head14295-sec-0025">
              <title>CONCLUSION</title>
              <p>These exploratory analyses of data from the PROMISE‐2 study in patients with CM suggest that an open‐ended question used to determine PI‐MBS provides potential benefits for investigating patient‐centric migraine treatment efficacy compared with other commonly evaluated PROMs. Correlations between PI‐MBS and other migraine‐specific PROMs were generally high, and improvement in PI‐MBS at week 12 consistently predicted improvement on PROMs, even after controlling for MMDs. The data obtained in these analyses provide insights beyond the standard measure of reduction in MMDs; thus, clinicians, trialists, and policymakers should consider longitudinal monitoring of PI‐MBS when evaluating the efficacy of preventive migraine treatments.</p>
            </sec>
            <sec sec-type="COI-statement" id="head14295-sec-0027">
              <title>CONFLICT OF INTEREST</title>
              <p>Dr. Lipton has been a consultant, advisory board member, and/or has received honoraria from Lundbeck Seattle BioPharmaceuticals, AEON, Allergan/Abbvie, American Academy of Neurology, American Headache Society, Amgen, Biohaven Pharmaceuticals, BioVision, Boston Scientific, Dr. Reddy's Laboratories, electroCore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Impel Neuropharma, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. In addition, he has received compensation from eNeura and Biohaven Pharmaceuticals, has stock or stock options in Biohaven Pharmaceuticals, Manistee, and has received research support from Amgen, Migraine Research Foundation, and National Headache Foundation. Dr. Goadsby has received grants and personal fees from Amgen and Eli Lilly, grants from Celgene, and personal fees from Aeon Biopharma, Alder Biopharmaceuticals, Allergan, Biohaven, Clexio, electroCore, eNeura, Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, Novartis, Pfizer, Sanofi, Santara Therapeutics, Teva, Trigemina, as well as personal fees from Massachusetts Medical Society, MedicoLegal work, Oxford University Press, Up‐to‐Date, and Wolters Kluwer; and reports a patent magnetic stimulation for headache assigned to eNeura without fee. Dr. Dodick reports over the past 12 months consulting fees from Allergan, Biohaven, Amgen, Atria, Cerecin, Clexio, Cooltech, Ctrl M, GlaxoSmithKline, Impel, Lundbeck, Nocira, Novartis, Pieris, Praxis, Revance, Axsome, Satsuma, Theranica, WL Gore. Honoraria: Speaking fees: Amgen, Eli Lilly, Lundbeck. Honoraria for CME activities: Academy for Continued Healthcare Learning, Cambridge University Press, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Majallin LLC, Medlogix Communications, Miller Medical Communications, MJH Lifesciences, Oxford University Press, Southern Headache Society (MAHEC), WebMD Health/Medscape, Wolters Kluwer. Research Support: American Migraine Foundation, Department of Defense, Henry Jackson Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute (PCORI), Sperling Foundation. Stock Options/Shareholder/Patents/Board of Directors: Aural analytics (Options), Ctrl M (Options), ExSano (Options), Atria Institute (Options), Epien (Options/Board), Healint (Options), Palion (Options), Nocira (Options), Second Opinion/Mobile Health (Options), Theranica (Options), King‐Devick Technologies (Options/Board), Matterhorn (Shares/Board), Ontologics (Shares/Board), Ayya Biosciences (options), Precon Health (Options/Board). Patent 17189376.1–1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis. Drs. McGinley, Houts, and Wirth are employees of Vector Psychometric Group, a company that received funding from H. Lundbeck A/S for time spent conducting this research. Dr. McGinley has also received research grants/support from Amgen and the National Headache Foundation and serves as the biostatistics editor for the journal <italic toggle="yes">Cephalalgia</italic>. Drs. Kymes, Ettrup, Østerberg, and Cady are employees of Lundbeck or one of its subsidiary companies and/or are stockholders in Lundbeck outside of the submitted work. Dr. Ashina is a principal investigator on clinical trials for AbbVie, Amgen, Eli Lilly, Lundbeck, and Novartis; has received personal fees from AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Percept Corporation, and Teva; has received research grants from Lundbeck Foundation, Novo Nordisk Foundation, and Novartis; and serves as an Associate Editor of <italic toggle="yes">Cephalalgia</italic>, Associate Editor of <italic toggle="yes">The Journal of Headache and Pain</italic>, and Associate Editor of <italic toggle="yes">Brain</italic>. He has no ownership interest and does not own stocks of any pharmaceutical company. Dr. Buse is a part‐time employee of Vector Psychometric Group, a company that received funding from H. Lundbeck A/S for time spent conducting this research; has received grant support from the National Headache Foundation; has received grant support and honoraria from Allergan, Amgen, Biohaven, Eli Lilly, Lundbeck, and Teva; and serves on the editorial board of <italic toggle="yes">Current Pain and Headache Reports</italic>.</p>
            </sec>
            <sec id="head14295-sec-0028">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><italic toggle="yes">Study concept and design</italic>: James S. McGinley, Carrie R. Houts, R. J. Wirth, Steve Kymes, Anders Ettrup, Ole Østerberg, Roger Cady. <italic toggle="yes">Acquisition of data</italic>: James S. McGinley, Carrie R. Houts, R. J. Wirth, Steve Kymes, Anders Ettrup, Ole Østerberg, Roger Cady. <italic toggle="yes">Analysis and interpretation of data</italic>: James S. McGinley, Carrie R. Houts, R. J. Wirth, Richard B. Lipton, Peter J. Goadsby, David W. Dodick, Steve Kymes, Anders Ettrup, Ole Østerberg, Roger Cady, Messoud Ashina, Dawn C. Buse. <italic toggle="yes">Drafting of the manuscript</italic>: James S. McGinley, Carrie R. Houts, R. J. Wirth. <italic toggle="yes">Revising it for intellectual content</italic>: Richard B. Lipton, Peter J. Goadsby, David W. Dodick, James S. McGinley, Carrie R. Houts, R. J. Wirth, Steve Kymes, Anders Ettrup, Ole Østerberg, Roger Cady, Messoud Ashina, Dawn C. Buse. <italic toggle="yes">Final approval of the completed manuscript</italic>: Richard B. Lipton, Peter J. Goadsby, David W. Dodick, James S. McGinley, Carrie R. Houts, R. J. Wirth, Steve Kymes, Anders Ettrup, Ole Østerberg, Roger Cady, Messoud Ashina, Dawn C. Buse.</p>
            </sec>
            <sec id="head14295-sec-0029">
              <title>CLINICAL TRIALS REGISTRATION NUMBER</title>
              <p>NCT02974153 (<ext-link xlink:href="http://www.ClinicalTrials.gov" ext-link-type="uri">www.ClinicalTrials.gov</ext-link>).</p>
            </sec>
          </body>
          <back>
            <ack id="head14295-sec-0026">
              <title>ACKNOWLEDGEMENTS</title>
              <p>The authors thank the patients, their families, and the study sites that participated in PROMISE‐2. The authors also thank Sally‐Anne Mitchell, PhD, of The Medicine Group, LLC (New Hope, PA) for providing medical writing support, which was funded by H. Lundbeck A/S (Copenhagen, Denmark) in accordance with Good Publication Practice guidelines.</p>
            </ack>
            <ref-list content-type="cited-references" id="head14295-bibl-0001">
              <title>REFERENCES</title>
              <ref id="head14295-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0001"><collab collab-type="authors">Headache Classification Committee of the International Headache Society (IHS)</collab>
. <article-title>The International Classification of Headache Disorders, 3rd edition</article-title>. <source>Cephalalgia</source>. <year>2018</year>;<volume>38</volume>:<fpage>1</fpage>‐<lpage>211</lpage>.</mixed-citation>
              </ref>
              <ref id="head14295-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0002"><string-name><surname>Lipton</surname><given-names>RB</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>WF</given-names></string-name>, <string-name><surname>Diamond</surname><given-names>S</given-names></string-name>, <string-name><surname>Diamond</surname><given-names>ML</given-names></string-name>, <string-name><surname>Reed</surname><given-names>M</given-names></string-name>. <article-title>Prevalence and burden of migraine in the United States: data from the American Migraine Study II</article-title>. <source>Headache</source>. <year>2001</year>;<volume>41</volume>:<fpage>646</fpage>‐<lpage>657</lpage>.<pub-id pub-id-type="pmid">11554952</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0003"><string-name><surname>Silberstein</surname><given-names>SD</given-names></string-name>. <article-title>Migraine symptoms: results of a survey of self‐reported migraineurs</article-title>. <source>Headache</source>. <year>1995</year>;<volume>35</volume>:<fpage>387</fpage>‐<lpage>396</lpage>.<pub-id pub-id-type="pmid">7672955</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0004"><string-name><surname>Vuralli</surname><given-names>D</given-names></string-name>, <string-name><surname>Ayata</surname><given-names>C</given-names></string-name>, <string-name><surname>Bolay</surname><given-names>H</given-names></string-name>. <article-title>Cognitive dysfunction and migraine</article-title>. <source>J Headache Pain</source>. <year>2018</year>;<volume>19</volume>:<elocation-id>109</elocation-id>.<pub-id pub-id-type="pmid">30442090</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0005"><string-name><surname>Goadsby</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Holland</surname><given-names>PR</given-names></string-name>, <string-name><surname>Martins‐Oliveira</surname><given-names>M</given-names></string-name>, <string-name><surname>Hoffmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Schankin</surname><given-names>C</given-names></string-name>, <string-name><surname>Akerman</surname><given-names>S</given-names></string-name>. <article-title>Pathophysiology of migraine: a disorder of sensory processing</article-title>. <source>Physiol Rev</source>. <year>2017</year>;<volume>97</volume>:<fpage>553</fpage>‐<lpage>622</lpage>.<pub-id pub-id-type="pmid">28179394</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0006"><string-name><surname>Burstein</surname><given-names>R</given-names></string-name>, <string-name><surname>Noseda</surname><given-names>R</given-names></string-name>, <string-name><surname>Borsook</surname><given-names>D</given-names></string-name>. <article-title>Migraine: multiple processes, complex pathophysiology</article-title>. <source>J Neurosci</source>. <year>2015</year>;<volume>35</volume>:<fpage>6619</fpage>‐<lpage>6629</lpage>.<pub-id pub-id-type="pmid">25926442</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0007"><string-name><surname>Munjal</surname><given-names>S</given-names></string-name>, <string-name><surname>Singh</surname><given-names>P</given-names></string-name>, <string-name><surname>Reed</surname><given-names>ML</given-names></string-name>, et al. <article-title>Most bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) study</article-title>. <source>Headache</source>. <year>2020</year>;<volume>60</volume>:<fpage>416</fpage>‐<lpage>429</lpage>.<pub-id pub-id-type="pmid">31837007</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0008"><string-name><surname>Chen</surname><given-names>PK</given-names></string-name>, <string-name><surname>Wang</surname><given-names>SJ</given-names></string-name>. <article-title>Non‐headache symptoms in migraine patients</article-title>. <source>F1000Res</source>. <year>2018</year>;<volume>7</volume>:<elocation-id>188</elocation-id>.<pub-id pub-id-type="pmid">29511532</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0009"><string-name><surname>Lipton</surname><given-names>RB</given-names></string-name>, <string-name><surname>Munjal</surname><given-names>S</given-names></string-name>, <string-name><surname>Alam</surname><given-names>A</given-names></string-name>, et al. <article-title>Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences</article-title>. <source>Headache</source>. <year>2018</year>;<volume>58</volume>:<fpage>1408</fpage>‐<lpage>1426</lpage>.<pub-id pub-id-type="pmid">30341895</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0010"><string-name><surname>Ashina</surname><given-names>M</given-names></string-name>. <article-title>Migraine</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>:<fpage>1866</fpage>‐<lpage>1876</lpage>.<pub-id pub-id-type="pmid">33211930</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="book" id="head14295-cit-0011"><collab collab-type="authors">Food and Drug Administration (FDA)</collab>
. <source>Migraine: Developing Drugs for Acute Treatment; Draft Guidance for Industry</source>; <year>2014</year>. Docket No. FDA–2014–D–1540. Accessed January 31, 2022. <ext-link xlink:href="https://www.govinfo.gov/content/pkg/FR-2014-10-22/pdf/2014-25048.pdf" ext-link-type="uri">https://www.govinfo.gov/content/pkg/FR‐2014‐10‐22/pdf/2014‐25048.pdf</ext-link>
</mixed-citation>
              </ref>
              <ref id="head14295-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="book" id="head14295-cit-0012"><collab collab-type="authors">Food and Drug Administration (FDA)</collab>
. <source>Migraine: Developing Drugs for Acute Treatment Guidance for Industry</source>. <publisher-name>U.S. Department of Health and Human Services</publisher-name>; <year>2018</year>. Accessed January 31, 2022. <ext-link xlink:href="https://www.fda.gov/media/89829/download" ext-link-type="uri">https://www.fda.gov/media/89829/download</ext-link>
</mixed-citation>
              </ref>
              <ref id="head14295-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0013"><string-name><surname>Diener</surname><given-names>HC</given-names></string-name>, <string-name><surname>Tassorelli</surname><given-names>C</given-names></string-name>, <string-name><surname>Dodick</surname><given-names>DW</given-names></string-name>, et al. <article-title>Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition</article-title>. <source>Cephalalgia</source>. <year>2019</year>;<volume>39</volume>(<issue>6</issue>):<fpage>687</fpage>‐<lpage>710</lpage>.<pub-id pub-id-type="pmid">30806518</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0014"><string-name><surname>Houts</surname><given-names>CR</given-names></string-name>, <string-name><surname>McGinley</surname><given-names>JS</given-names></string-name>, <string-name><surname>Nishida</surname><given-names>TK</given-names></string-name>, et al. <article-title>Systematic review of outcomes and endpoints in acute migraine clinical trials</article-title>. <source>Headache</source>. <year>2021</year>;<volume>61</volume>:<fpage>263</fpage>‐<lpage>275</lpage>.<pub-id pub-id-type="pmid">33611818</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0015"><string-name><surname>Lipton</surname><given-names>RB</given-names></string-name>, <string-name><surname>Goadsby</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Smith</surname><given-names>J</given-names></string-name>, et al. <article-title>Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE‐2</article-title>. <source>Neurology</source>. <year>2020</year>;<volume>94</volume>:<fpage>e1365</fpage>‐<lpage>e1377</lpage>.<pub-id pub-id-type="pmid">32209650</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0016"><string-name><surname>Silberstein</surname><given-names>S</given-names></string-name>, <string-name><surname>Diamond</surname><given-names>M</given-names></string-name>, <string-name><surname>Hindiyeh</surname><given-names>NA</given-names></string-name>, et al. <article-title>Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE‐2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study</article-title>. <source>J Headache Pain</source>. <year>2020</year>;<volume>21</volume>:<elocation-id>120</elocation-id>.<pub-id pub-id-type="pmid">33023473</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0017"><collab collab-type="authors">Headache Classification Committee of the International Headache Society (IHS)</collab>
. <article-title>The International Classification of Headache Disorders, 3rd edition (beta version)</article-title>. <source>Cephalalgia</source>. <year>2013</year>;<volume>33</volume>:<fpage>629</fpage>‐<lpage>808</lpage>.<pub-id pub-id-type="pmid">23771276</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="book" id="head14295-cit-0018"><string-name><surname>Guy</surname><given-names>W</given-names></string-name>. <source>ECDEU Assessment Manual for Psychopharmacology</source>. <publisher-name>U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs</publisher-name>; <year>1976</year>.</mixed-citation>
              </ref>
              <ref id="head14295-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0019"><string-name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></string-name>. <article-title>SF‐36 health survey update</article-title>. <source>Spine</source>. <year>2000</year>;<volume>25</volume>:<fpage>3130</fpage>‐<lpage>3139</lpage>.<pub-id pub-id-type="pmid">11124729</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0020"><string-name><surname>Herdman</surname><given-names>M</given-names></string-name>, <string-name><surname>Gudex</surname><given-names>C</given-names></string-name>, <string-name><surname>Lloyd</surname><given-names>A</given-names></string-name>, et al. <article-title>Development and preliminary testing of the new five‐level version of EQ‐5D (EQ‐5D‐5L)</article-title>. <source>Qual Life Res</source>. <year>2011</year>;<volume>20</volume>:<fpage>1727</fpage>‐<lpage>1736</lpage>.<pub-id pub-id-type="pmid">21479777</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0021"><string-name><surname>Kosinski</surname><given-names>M</given-names></string-name>, <string-name><surname>Bayliss</surname><given-names>MS</given-names></string-name>, <string-name><surname>Bjorner</surname><given-names>JB</given-names></string-name>, et al. <article-title>A six‐item short‐form survey for measuring headache impact: the HIT‐6</article-title>. <source>Qual Life Res</source>. <year>2003</year>;<volume>12</volume>:<fpage>963</fpage>‐<lpage>974</lpage>.<pub-id pub-id-type="pmid">14651415</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0022"><string-name><surname>Houts</surname><given-names>CR</given-names></string-name>, <string-name><surname>McGinley</surname><given-names>JS</given-names></string-name>, <string-name><surname>Wirth</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Cady</surname><given-names>R</given-names></string-name>, <string-name><surname>Lipton</surname><given-names>RB</given-names></string-name>. <article-title>Reliability and validity of the 6‐item Headache Impact Test in chronic migraine from the PROMISE‐2 study</article-title>. <source>Qual Life Res</source>. <year>2021</year>;<volume>30</volume>:<fpage>931</fpage>‐<lpage>943</lpage>.<pub-id pub-id-type="pmid">33079313</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0023"><string-name><surname>Houts</surname><given-names>CR</given-names></string-name>, <string-name><surname>Wirth</surname><given-names>RJ</given-names></string-name>, <string-name><surname>McGinley</surname><given-names>JS</given-names></string-name>, <string-name><surname>Cady</surname><given-names>R</given-names></string-name>, <string-name><surname>Lipton</surname><given-names>RB</given-names></string-name>. <article-title>Determining thresholds for meaningful change for the Headache Impact Test (HIT‐6) total and item‐specific scores in chronic migraine</article-title>. <source>Headache</source>. <year>2020</year>;<volume>60</volume>:<fpage>2003</fpage>‐<lpage>2013</lpage>.<pub-id pub-id-type="pmid">32862469</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="book" id="head14295-cit-0024"><string-name><surname>Anderson</surname><given-names>TW</given-names></string-name>. <source>An Introduction to Multivariate Statistical Analysis</source>. <edition>3</edition>rd ed. <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>; <year>2003</year>.</mixed-citation>
              </ref>
              <ref id="head14295-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="book" id="head14295-cit-0025"><string-name><surname>Morrison</surname><given-names>DF</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>LC</given-names></string-name>, <string-name><surname>Sahlin</surname><given-names>HL</given-names></string-name>. <source>Multivariate Statistical Methods</source>. <edition>2</edition>nd ed. <publisher-name>McGraw‐Hill</publisher-name>; <year>1976</year>.</mixed-citation>
              </ref>
              <ref id="head14295-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0026"><string-name><surname>Perlman</surname><given-names>MD</given-names></string-name>. <article-title>Unbiasedness of the likelihood ratio tests for equality of several covariance matrices and equality of several multivariate normal populations</article-title>. <source>Ann Stat</source>. <year>1980</year>;<volume>8</volume>:<fpage>247</fpage>‐<lpage>263</lpage>.</mixed-citation>
              </ref>
              <ref id="head14295-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0027"><string-name><surname>McGinley</surname><given-names>JS</given-names></string-name>, <string-name><surname>Houts</surname><given-names>CR</given-names></string-name>, <string-name><surname>Nishida</surname><given-names>TK</given-names></string-name>, et al. <article-title>Systematic review of outcomes and endpoints in preventive migraine clinical trials</article-title>. <source>Headache</source>. <year>2021</year>;<volume>61</volume>:<fpage>253</fpage>‐<lpage>262</lpage>.<pub-id pub-id-type="pmid">33600610</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0028"><string-name><surname>Cohen</surname><given-names>J</given-names></string-name>. <article-title>A power primer</article-title>. <source>Psychol Bull</source>. <year>1992</year>;<volume>112</volume>:<fpage>155</fpage>‐<lpage>159</lpage>.<pub-id pub-id-type="pmid">19565683</pub-id></mixed-citation>
              </ref>
              <ref id="head14295-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="book" id="head14295-cit-0029"><string-name><surname>Cohen</surname><given-names>J</given-names></string-name>. <source>Statistical Power Analysis for the Behavioral Sciences</source>. <edition>2</edition>nd ed. <publisher-name>Lawrence Erlbaum Associates</publisher-name>; <year>1988</year>.</mixed-citation>
              </ref>
              <ref id="head14295-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="head14295-cit-0030"><string-name><surname>Zhao</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Ong</surname><given-names>JJY</given-names></string-name>, <string-name><surname>Goadsby</surname><given-names>PJ</given-names></string-name>. <article-title>Emerging treatment options for migraine</article-title>. <source>Ann Acad Med Singap</source>. <year>2020</year>;<volume>49</volume>:<fpage>226</fpage>‐<lpage>235</lpage>.<pub-id pub-id-type="pmid">32419007</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
